CR10600A - Ciclopenta (d) pirimidinas hidroxiladas y metoxiladas como inhibidores de akt proteina quinasa - Google Patents

Ciclopenta (d) pirimidinas hidroxiladas y metoxiladas como inhibidores de akt proteina quinasa

Info

Publication number
CR10600A
CR10600A CR10600A CR10600A CR10600A CR 10600 A CR10600 A CR 10600A CR 10600 A CR10600 A CR 10600A CR 10600 A CR10600 A CR 10600A CR 10600 A CR10600 A CR 10600A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
protein kinase
metoxyled
pyrimidins
cyclopenta
Prior art date
Application number
CR10600A
Other languages
English (en)
Spanish (es)
Inventor
F Blake James
Xu Rui
C Kallan Nicholas
Xiao Dengming
Lee Spencer Ketih
R Bencsik Josef
Liang Jun
Safina Brian
Zhang Birong
Chabot Christine
Do Steven
M Wallace Eli
L Banka Anna
T Schlachter Stephen
s mitchell Ian
Original Assignee
Genentech Inc
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38686743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10600(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Array Biopharma Inc filed Critical Genentech Inc
Publication of CR10600A publication Critical patent/CR10600A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pregnancy & Childbirth (AREA)
  • AIDS & HIV (AREA)
  • Psychology (AREA)
CR10600A 2006-07-06 2009-02-05 Ciclopenta (d) pirimidinas hidroxiladas y metoxiladas como inhibidores de akt proteina quinasa CR10600A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81871806P 2006-07-06 2006-07-06

Publications (1)

Publication Number Publication Date
CR10600A true CR10600A (es) 2009-02-20

Family

ID=38686743

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10600A CR10600A (es) 2006-07-06 2009-02-05 Ciclopenta (d) pirimidinas hidroxiladas y metoxiladas como inhibidores de akt proteina quinasa

Country Status (34)

Country Link
EP (4) EP2399909B1 (en, 2012)
JP (4) JP5266216B2 (en, 2012)
KR (5) KR20150051240A (en, 2012)
CN (2) CN101578273B (en, 2012)
AR (3) AR061842A1 (en, 2012)
AT (1) ATE524447T1 (en, 2012)
AU (1) AU2007269060B2 (en, 2012)
BR (3) BRPI0713923B8 (en, 2012)
CA (2) CA2836316A1 (en, 2012)
CL (1) CL2007001993A1 (en, 2012)
CO (1) CO6150161A2 (en, 2012)
CR (1) CR10600A (en, 2012)
CY (1) CY1112117T1 (en, 2012)
DK (2) DK2402325T3 (en, 2012)
ES (3) ES2554228T3 (en, 2012)
HR (1) HRP20110908T1 (en, 2012)
HU (1) HUE026237T2 (en, 2012)
IL (2) IL196028A (en, 2012)
IN (1) IN2014KN02886A (en, 2012)
MA (1) MA31655B1 (en, 2012)
MX (4) MX377920B (en, 2012)
MY (1) MY147364A (en, 2012)
NO (1) NO342346B1 (en, 2012)
NZ (3) NZ610633A (en, 2012)
PL (2) PL2049501T3 (en, 2012)
PT (1) PT2049501E (en, 2012)
RS (1) RS52212B (en, 2012)
RU (2) RU2478632C2 (en, 2012)
SG (4) SG184706A1 (en, 2012)
SI (2) SI2049501T1 (en, 2012)
TW (2) TW201332994A (en, 2012)
UA (1) UA95641C2 (en, 2012)
WO (1) WO2008006040A1 (en, 2012)
ZA (1) ZA200900070B (en, 2012)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
EP2054418B1 (en) * 2006-07-06 2011-11-09 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
EP2049546B1 (en) * 2006-07-06 2010-12-29 Array Biopharma, Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US8003651B2 (en) 2006-07-06 2011-08-23 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US20110135569A1 (en) 2007-03-20 2011-06-09 Peak Biosciences Inc. Method for therapeutic administration of radionucleosides
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
SG185274A1 (en) 2007-07-05 2012-11-29 Array Biopharma Inc Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ES2533557T3 (es) 2007-07-05 2015-04-13 Array Biopharma, Inc. Pirimidil ciclopentanos como inhibidores de proteína cinasa AKT
JP5635910B2 (ja) * 2008-01-09 2014-12-03 アレイ バイオファーマ、インコーポレイテッド ＡＫＴタンパク質キナーゼ阻害剤としての５Ｈ−シクロペンタ［ｄ］ピリミジン
NZ586346A (en) * 2008-01-09 2012-02-24 Array Biopharma Inc Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
PE20091315A1 (es) 2008-01-09 2009-09-21 Array Biopharma Inc Ciclopentanos de pirimidilo como inhibidores de la proteina cinasa akt
KR101624752B1 (ko) * 2008-01-09 2016-05-26 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 저해물질로써의 수산화된 피리미딜 시클로펜탄
JP2014507129A (ja) * 2010-12-23 2014-03-27 ジェネンテック， インコーポレイテッド 腫瘍の治療のためのオートファジー誘導剤及び阻害剤の併用療法
WO2012135749A2 (en) * 2011-04-01 2012-10-04 Genentech, Inc. Biomarkers for predicting sensitivity to cancer treatments
TR201815685T4 (tr) * 2011-04-01 2018-11-21 Genentech Inc Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
EP2694485B1 (en) 2011-04-01 2017-11-15 Genentech, Inc. Combination of akt inhibitor compound and vemurafenib for use in therapeutic treatments
EP2861583B1 (en) * 2012-05-17 2016-06-29 Array Biopharma, Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
MA37647A1 (fr) * 2012-05-17 2016-03-31 Genentech Inc Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci
MY169028A (en) 2012-05-17 2019-02-04 Genentech Inc Process for making hydroxylated cyclopentylpyrimidine compounds
HRP20180948T1 (hr) * 2012-05-17 2018-08-10 Genentech, Inc. Postupak za proizvodnju aminokiselinskih spojeva
KR20240066293A (ko) 2012-05-17 2024-05-14 제넨테크, 인크. 무정형 형태의 akt 저해성 피리미디닐 - 사이클로펜탄 화합물, 조성물 및 이들의 방법
US20150258127A1 (en) 2012-10-31 2015-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
CN104968363A (zh) * 2012-12-07 2015-10-07 综合医院公司 Pi3k/akt抑制剂化合物与her3/egfr抑制剂化合物的组合及使用方法
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
MX385726B (es) * 2013-11-15 2025-03-18 Hoffmann La Roche Procesos para la preparación de compuestos de pirimidinilciclopentano.
KR102513869B1 (ko) * 2014-09-26 2023-03-23 에프. 호프만-라 로슈 아게 (시클로펜틸[d]피리미딘-4-일)피페라진 화합물의 제조 방법
EP4613333A2 (en) 2016-08-10 2025-09-10 F. Hoffmann-La Roche AG Pharmaceutical compositions comprising akt protein kinase inhibitors
AU2017348322B8 (en) 2016-10-28 2021-12-23 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating EZH2-mediated cancer
CN112154146A (zh) * 2018-03-06 2020-12-29 西奈山伊坎医学院 丝氨酸苏氨酸激酶(akt)降解/破坏化合物和使用方法
US12110295B2 (en) 2018-06-21 2024-10-08 Icahn School Of Medicine At Mount Sinai WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds and methods of use
JP2022515371A (ja) 2018-12-19 2022-02-18 ジェネンテック， インコーポレイテッド Ａｋｔ阻害剤、タキサンおよびｐｄ－ｌ１阻害剤を含む併用療法を用いた乳癌の処置
KR20210107069A (ko) 2018-12-21 2021-08-31 다이이찌 산쿄 가부시키가이샤 항체-약물 컨쥬게이트와 키나아제 저해제의 조합
CN117964620A (zh) 2019-01-29 2024-05-03 南京正大天晴制药有限公司 Akt抑制剂
US20220249511A1 (en) 2019-03-29 2022-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
CN113645972A (zh) * 2019-04-09 2021-11-12 达纳-法伯癌症研究所有限公司 通过atp-竞争性akt抑制剂gdc-0068与e3连接酶配体的接合降解akt及使用方法
WO2021185238A1 (zh) * 2020-03-17 2021-09-23 江苏恒瑞医药股份有限公司 稠合二环类衍生物、其制备方法及其在医药上的应用
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
WO2021254920A1 (en) 2020-06-16 2021-12-23 F. Hoffmann-La Roche Ag Process for making hydroxylated cyclopentylpyrimidine compounds
AU2021314419B2 (en) 2020-07-22 2023-12-07 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Salt of dihydropyrido[2,3-d]pyrimidinone derivative, preparation method therefor, and use thereof
TWI750905B (zh) * 2020-11-19 2021-12-21 財團法人國家衛生研究院 噻唑化合物作為蛋白質激酶抑制劑
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물
WO2023043869A1 (en) * 2021-09-15 2023-03-23 Teva Pharmaceuticals International Gmbh Solid state forms of ipatasertib citrate
CN113788834B (zh) * 2021-09-18 2022-11-29 河南奥思恩医药科技有限公司 2,4-二氯-6,7-二氢-5H-吡咯并[3,4-d]嘧啶盐酸盐的制备方法
CN117677614A (zh) * 2021-12-17 2024-03-08 中国医药研究开发中心有限公司 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途
IL315848A (en) 2022-03-31 2024-11-01 Astrazeneca Ab Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment
CN120051280A (zh) 2022-10-17 2025-05-27 阿斯利康(瑞典)有限公司 用于治疗癌症的serd的组合
CN120187416A (zh) 2022-11-11 2025-06-20 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
WO2024160843A1 (en) 2023-01-31 2024-08-08 F. Hoffmann-La Roche Ag Mutant ketoreductase with increased ketoreductase activity as well as methods and uses involving the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
NL7112938A (en, 2012) * 1970-09-30 1972-04-05
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
DK0958285T3 (da) * 1997-01-08 2004-05-17 Hoffmann La Roche Tricykliske benzo[e]isoindoler og benzol[h]isoquinoliner
ES2152902B1 (es) * 1999-07-27 2001-08-16 Medichem Sa Procedimiento de obtencion de venlafaxina
CZ304061B6 (cs) * 2000-08-18 2013-09-11 Millennium Pharmaceuticals, Inc. Derivát chinazolinu, farmaceutická kompozice a lécivo s jeho obsahem
DE60128709T2 (de) * 2000-09-15 2007-12-27 Vertex Pharmaceuticals Inc., Cambridge Triazol-verbindungen als protein-kinase-inhibitoren
BR0208593A (pt) * 2001-03-30 2006-02-21 King Pharmaceuticals Res & Dev método para o tratamento de um mamìfero, composto, e, composição farmacêutica
AU2002357043B2 (en) * 2001-12-06 2008-04-24 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
US6924290B2 (en) * 2002-01-23 2005-08-02 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
NZ590160A (en) 2003-11-21 2012-07-27 Array Biopharma Inc AKT protein kinase inhibitors
ATE464303T1 (de) * 2004-04-28 2010-04-15 Vertex Pharma Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
WO2005113762A1 (en) 2004-05-18 2005-12-01 Pfizer Products Inc. CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF
EP1866822A4 (en) * 2005-03-03 2010-09-01 Burnham Inst Medical Research SCREENING PROCEDURE FOR PROTEIN KINASE B INHIBITORS USING VIRTUAL DOCKING APPARATUS AND COMPOSITIONS AND COMPOSITIONS DISCOVERED THEREFOR
US8003651B2 (en) * 2006-07-06 2011-08-23 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
EP2054418B1 (en) * 2006-07-06 2011-11-09 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors

Also Published As

Publication number Publication date
EP2399909A1 (en) 2011-12-28
WO2008006040A1 (en) 2008-01-10
DK2402325T3 (en) 2015-12-07
SG188905A1 (en) 2013-04-30
BRPI0713923A2 (pt) 2013-07-02
CY1112117T1 (el) 2015-11-04
CA2656622C (en) 2017-09-12
IN2014KN02886A (en, 2012) 2015-05-08
EP2399909B1 (en) 2015-08-26
HUE026237T2 (en) 2016-06-28
BRPI0713923B8 (pt) 2021-05-25
JP5266216B2 (ja) 2013-08-21
AR093810A2 (es) 2015-06-24
PL2402325T3 (pl) 2016-01-29
KR101178672B1 (ko) 2012-09-07
SI2049501T1 (sl) 2012-01-31
MA31655B1 (fr) 2010-09-01
CN101578273A (zh) 2009-11-11
MX337843B (es) 2016-03-22
HRP20110908T1 (hr) 2012-02-29
EP2049501A1 (en) 2009-04-22
ES2554228T3 (es) 2015-12-17
AU2007269060B2 (en) 2014-02-20
RU2009103900A (ru) 2010-08-20
AR061842A1 (es) 2008-09-24
EP2402325B1 (en) 2015-08-26
MX366319B (es) 2019-07-05
TW201332994A (zh) 2013-08-16
KR20150051240A (ko) 2015-05-11
KR20090030333A (ko) 2009-03-24
CL2007001993A1 (es) 2008-06-20
RU2478632C2 (ru) 2013-04-10
CA2836316A1 (en) 2008-01-10
CN101578273B (zh) 2012-11-14
CO6150161A2 (es) 2010-04-20
KR20140093291A (ko) 2014-07-25
ZA200900070B (en) 2010-03-31
CN102816124A (zh) 2012-12-12
JP2013177470A (ja) 2013-09-09
JP5836294B2 (ja) 2015-12-24
BR122013028012B8 (pt) 2021-05-25
RU2012155606A (ru) 2014-06-27
BRPI0713923B1 (pt) 2020-09-29
NZ573732A (en) 2012-03-30
NO342346B1 (no) 2018-05-07
PT2049501E (pt) 2011-12-30
EP2966065A3 (en) 2016-03-02
ES2554252T3 (es) 2015-12-17
ES2372774T3 (es) 2012-01-26
BR122013028012B1 (pt) 2021-04-06
EP2966065A2 (en) 2016-01-13
RS52212B (en) 2012-10-31
TW200817373A (en) 2008-04-16
AU2007269060A1 (en) 2008-01-10
JP2014231530A (ja) 2014-12-11
JP2009542723A (ja) 2009-12-03
KR101495408B1 (ko) 2015-02-25
MY147364A (en) 2012-11-30
MX2019008117A (es) 2019-09-04
HK1160638A1 (en) 2012-08-10
NZ597647A (en) 2013-08-30
AR109424A2 (es) 2018-11-28
BR122013028005B8 (pt) 2021-05-25
PL2049501T3 (pl) 2012-02-29
TWI402266B (zh) 2013-07-21
SG184706A1 (en) 2012-10-30
ATE524447T1 (de) 2011-09-15
IL241705A0 (en) 2015-11-30
EP2402325A2 (en) 2012-01-04
JP2013091670A (ja) 2013-05-16
BR122013028005B1 (pt) 2021-04-06
KR101578877B1 (ko) 2016-02-22
UA95641C2 (xx) 2011-08-25
SG10201802127UA (en) 2018-04-27
IL196028A0 (en) 2009-09-01
HK1160134A1 (en) 2012-08-10
SG185980A1 (en) 2012-12-28
NZ610633A (en) 2014-12-24
MX2008016202A (es) 2009-02-11
NO20090581L (no) 2009-04-06
IL196028A (en) 2017-02-28
KR20130029364A (ko) 2013-03-22
HK1126768A1 (en) 2009-09-11
EP2049501B1 (en) 2011-09-14
KR20130141717A (ko) 2013-12-26
EP2402325A3 (en) 2012-06-13
DK2049501T3 (da) 2011-12-12
MX377920B (es) 2025-03-11
CA2656622A1 (en) 2008-01-10
SI2402325T1 (sl) 2015-12-31

Similar Documents

Publication Publication Date Title
CR10600A (es) Ciclopenta (d) pirimidinas hidroxiladas y metoxiladas como inhibidores de akt proteina quinasa
CR10601A (es) Ciclopenta (d) pirimidinas como inhibidores de la proteina cinasa akt
ECSP109937A (es) Pirimidil ciclopentanos como inhibidores de la proteína quinasa akt.
ATE522509T1 (de) Pyrimidylcyclopentane als inhibitoren der akt- proteinkinase
CO6311051A2 (es) Compuestos de pirimidina, composiciones y metodos de uso
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
CR8929A (es) Polimorfo ii de rapamicina y usos del mismo
CR10573A (es) Derivados del pirazol como inhibidores del citocromo p450
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
ECSP088306A (es) Agentes para prevenir y tratar los trastornos que involucran la modulación de los receptores ryr
CR11370A (es) Inhibidores de quinasas simil polo
DOP2009000242A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cancer
ECSP10010389A (es) Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa
CO6280510A2 (es) Pirimidil ciclopentanos hidroxilados como inhibidores de akt proteina quinasa
UA104410C2 (uk) Піримідилциклопентани як інгібітори протеїнкіназ акт
DOP2009000143A (es) Quinazolinas para la inhibicion de pdk1